Filing Flows › Zomedica (ZOMDF) › Q3 2025
Zomedica (ZOMDF) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 4, 2025
Zomedica (ZOMDF) reported revenue of $8.1M for the third quarter 2025 (Q3 2025), +16% from a year earlier and +16% from the quarter before. Operating margin was -81.6%, net loss $6.1M (75.6% of revenue).
Zomedica, Q3 2025: revenue $8.1M (+16% year over year), operating margin -81.6%, net loss $6.1M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.1M | +16% | +16% |
| Operating profit | −$6.6M | — | — |
| Net earnings | −$6.1M | — | — |
| Operating cash flow | −$4.7M | — | — |
What changed
Revenue was $8.1M in Q3 2025, up 16% year over year and up 16% from the previous quarter. Consumables was the largest line at 66% of revenue. Consumables added $672K year over year (up 14%), 61% of the total change. Other declined 23%.
Gross margin was 67.2%, down 5.2 points from a year earlier. Operating costs exceeded revenue by $6.6M, an operating margin of -81.6%. Operating expenses fell 4% while revenue rose 16%. The fastest-growing cost line was Sales & marketing (+12%). The quarter ended with a net loss of $6.1M, narrower than the previous quarter's $7.4M loss.
Operating cash flow was −$4.7M. Non-cash charges added back $1.9M of depreciation and amortization and $867K of share-based compensation. Working capital and other items used $1.3M. Capital expenditures of $43K exceeded it, leaving free cash flow of −$4.7M.
Questions
What was Zomedica's revenue in the third quarter 2025?
Zomedica (ZOMDF) reported revenue of $8.1M for the third quarter 2025 (Q3 2025), +16% from a year earlier and +16% from the quarter before.
Was Zomedica profitable in the third quarter 2025?
Operating loss was $6.6M (-81.6% of revenue) and net loss $6.1M.
Source: Zomedica 10-Q on SEC EDGAR.